Bio
Dr. Gabriel Mannis is Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, and Medical Director of Stanford’s Inpatient Leukemia Service. He specializes in the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. As a clinical scientist, Dr. Mannis divides his time between caring for patients, teaching trainees, and researching novel therapies for AML and MDS. Dr. Mannis has co-authored numerous publications on topics including AML, hematopoietic cell transplantation, and advanced care planning for patients with hematologic malignancies. Currently, Dr. Mannis serves on the National Comprehensive Cancer Network AML panel, helping to write evidence-based guidelines for how AML is best treated. He oversees the AML clinical trial portfolio at Stanford, with multiple clinical trials of novel drugs actively enrolling for both newly diagnosed and relapsed or refractory AML.
